Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GA101-miniCHOP in Elderly Unfit DLBCL
NCT02495454Phase 2Terminated
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Aug 2015
- Primary completion
- Mar 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of obinutuzumab in diffuse large B-cell lymphoma (DLBCL), sponsored by Fondazione Italiana Linfomi. Started Aug 2015; status: terminated.
02
Drugs
obinutuzumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02495454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02495454.